Scientific Projects
Area A – Pathomechanisms of Vascular Remodelling - Hypoxia
- WP-A1: Role of oxygenation and redox changes in cells involved in pulmonary vascular remodelling (Fandrey), Universität Duisburg/Essen
- WP-A2: Oxygen-sensing by ion channels and hypoxia-induced vascular remodelling (Lopez-Barneo) University of Sevilla
- WP-A3: Role of HIF and HIF hydroxylases and related molecules in vascular remodelling (Pugh) University of Oxford
- WP-A4: Erythropoietin has an ”anti-pulmonary hypertensive” effect in the lung (Gassmann) University of Zurich
- WP-A5: Gene expression profiling and redox changes in intact lungs from animals with hypoxia-induced pulmonary hypertension. (Weissmann) UGLC
Area B – Pathomechanisms of Vascular Remodelling - Inflammation and Coagulation
- WP-B1: Chemokines in pulmonary vascular remodelling (Humbert/Simonneau) Hôpital A. Béclère, Clamart
- WP-B2: Interplay of coagulation and endothelial cell biology in chronic thromboembolic pulmonary hypertension (Lang/Klepetko & Olschewski/Preissner) Medical University Vienna & Medical University Graz/UGLC
Area C – Pathomechanisms of Vascular Remodelling – Mechanical Stress
- WP-C1: In Vitro models to study vascular cell proliferation in plexiform lesions (Welte/Hoeper), Medical School Hannover
- WP-C2: Angiopoietin-1/BMPR2 signalling in overcirculation-associated pulmonary arterial hypertension (Naeije) Université Libre de Bruxelles
- WP-C3: Functional genomics of lung vascular remodelling in pulmonary venous hypertension (Kuebler) Charité, Institute of Physiology, Berlin
Area D – Cell-Cell Interaction and Progenitor Cells in Vascular Remodelling
- WP-D1: Role and therapeutic potential of stem cells in pulmonary vascular remodelling (Seeger/Braun) UGLC
- WP-D2: Endothelial progenitor cells (EPC) and circulating fibrocytes (CFC) in FPAH/IPAH (Pepke-Zaba/Morrell) University of Cambridge
- WP-D3: Cellular and molecular mechanisms of pulmonary vascular remodeling in chronic obstructive pulmonary disease (COPD) (Barbera) Hospital Clinic I Provincial de Barcelona
Area E - Growth Mediators in Vascular Remodelling
- WP-E1: Functional genomics of the TGF-b/BMP superfamily in pulmonary vascular remodelling(Morrell/Trembath) University of Cambridge/ King´s College London
- WP-E2: BMP-induced signal transduction: Ligand-induced phosphoproteome analysis and whole genome location studies of smad binding sites in pulmonary hypertension (Eickelberg) UGLC
- WP-E3: Dysregulation of the serotonin pathway in human pulmonary hypertension (Adnot/Eddahibi) INSERM Institute Paris(Institute Nationale de Recherche Medicale
- WP-E4: Pulmonary vascular phenotypes in genetically modified mice: In vivo interactions between the BMPRII and serotonin systems (MacLean) University of Glasgow
- WP-E5: Angiogenesis and endothelial cell remodelling in pulmonary hypertension (Christoforidis) University of Ioannina, Greece
Area F – Anti-remodelling Strategies – Molecular Targets
- WP-F1: Genetic background of familial/idiopathic pulmonary arterial hypertension (Janssen) Universitätsklinikum Heidelberg
- WP-F2: Generation and metabolism of dimethylated arginines in pulmonary hypertension (Vallance/ Leiper) University College London
- WP-F3: Role of tetrahydrobiopterin in regulation of pulmonary vascular tone and structure (Wilkins/Channon) Imperial College London
- WP-F4: Guanylate cyclase stimulation as novel anti-remodelling therapy in pulmonary hypertension (Grimminger) UGLC
Area G – Anti-remodelling Strategies – Preclinical and Clinical Studies
- WP-G1: Phosphodiesterase (PDE) inhibition for treatment of pulmonary arterial hypertension – PDE profiling and anti-remodelling targeting (Schudt) Altanapharma
- WP-G2: Statins as add-on therapy in severe pulmonary arterial hypertension- phase two study (Gruenig) Universitätsklinikum Heidelberg
- WP-G3: Imaging of anti-remodelling strategies in PAH patients: relationship with genetic background (Peacock & Galie) Scottish Pulmonary Vascular Unit, Glasgow / Bologna Pulmonary Hypertension Centre
Area H – Core Facilities and Management
- WP-H1: European PH Registry (Galie) Bologna Pulmonary Hypertension Centre
- WP-H2: European PH Tissue Bank (Grimminger & Klepetko & Humbert) UGLC / Medical University Vienna / Hôpital A. Béclère, Clamart
- WP-H3: Clinical Trial Network (Coordinator Team) UGLC
- WP-H4: cDNA Microarray Platform (Genolyze) Genolyze Ltd, Turku, Finland
- WP-H5: Proteomic Platform (Alphalyse) Alphalyse A/S Odense, Denmark
- WP-H6: Training and Technology Transfer (Eickelberg) UGLC
- WP-H7: Management (Coordinator Team) UGLC
- WP-H8: Ethical Review Board UGLC
Previous page: Collaborating Centers
Next page: Principal Investigators